Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, has announced the pricing of its underwritten offering of 2,727,273 shares of its Class A common stock at an offering price of US$11.00 per share. The gross proceeds from the offering are expected to be US$30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All shares in the offering will be offered by Immuneering.
Latham & Watkins LLP represents Immuneering in the offering with a capital markets team led by New York partner Nathan Ajiashvili and Boston partners Jennifer Yoon and Evan Smith, with Chicago associate Omeed Valipour and Boston associate Alison Vitello.
